Recurrence of depressive disorders after interferon-induced depression

Translational Psychiatry

Volumn 7, Issue 2, 2017, Pages

  Chiu, W C ^a,b   Su, Y P ^a,b   Su, K P ^c,d   Chen, P C ^e,f  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DEPRESSION; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RECURRENT DISEASE; REIMBURSEMENT; REMISSION; URBANIZATION; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHRONIC HEPATITIS C; INCIDENCE; MAJOR DEPRESSION; PROPORTIONAL HAZARDS MODEL; TAIWAN;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TAIWAN;

EID: 85011891545     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.274     Document Type: Article

References (44)

1. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 1000-1006.
2. Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J Clin Psychiatry 2001; 62(Suppl 22): 5-9.
3. Steinert C, Hofmann M, Kruse J, Leichsenring F. The prospective long-term course of adult depression in general practice and the community. A systematic literature review. J Affect Disord 2014; 152-154: 65-75.
4. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008; 65: 513-520.
5. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010; 122: 184-191.
6. Bhagwagar Z, Cowen PJ. 'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med 2008; 38: 307-313.
7. Mocking RJ, Figueroa CA, Rive MM, Geugies H, Servaas MN, Assies J et al. Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study. BMJ Open 2016; 6: e009510.
8. Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007; 16: 186-201.
9. Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010; 67: 550-557.
10. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128-1138.
11. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.
12. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451.
13. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F et al. Interferon alpha (IFNalpha) and psychiatric syndromes: A review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 731-746.
14. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
15. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferonalpha therapy: a prospective study. Gen Hosp Psychiatry 2003; 25: 34-38.
16. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Calès P, Garré JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003; 4: 115-118.
17. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013; 31: 1514-1521.
18. Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2015; 63: 1111-1117.
19. National Health Research Institutes. National Health Insurance Research Database. Available at http://nhird.nhri.org.tw/en/index.htm. Accessed 27 May 2013.
20. Centers for Disease Control, Department of Health, Taiwan Guideline for communicable disease surveillance. Available at https://www.cdc.gov.tw/uploads/ files/201304/d7a9864a-ddb0-4c06-9d3b-1cd3755efae3.pdf.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, USA, 2000.
22. Chen MH, Li CT, Tsai CF, Lin WC, Chang WH, Chen TJ et al. Risk of subsequent dementia among patients with bipolar disorder or major depression: a nationwide longitudinal study in Taiwan. J Am Med Dir Assoc 2015; 16: 504-508.
23. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819-824.
24. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-435.
25. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol 2012; 32: 531-543.
26. Robinson OJ, Sahakian BJ. Recurrence in major depressive disorder: a neurocognitive perspective. Psychol Med 2008; 38: 315-318.
27. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 2002; 27: 852-861.
28. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-2522.
29. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
30. Smith AK, Simon JS, Gustafson EL, Noviello S, Cubells JF, Epstein MP et al. Association of a polymorphism in the indoleamine-2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry 2012; 17: 781-789.
31. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD et al. Impaired repression at a 5-hydroxytryptamine 1 A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003; 23: 8788-8799.
32. Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch KP, Scheurlen M. Serotonin-1 A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007; 132: 1279-1286.
33. Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D et al. Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression. Int J Neuropsychopharmacol 2016; 19, pyv135.
34. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferonalpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342-1345.
35. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010; 15: 535-547.
36. Bockting CL, Lok A, Visser I, Assies J, Koeter MW, Schene AH et al. Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study. Psychiatry Res 2012; 200: 281-287.
37. Mocking RJ, Pellikaan CM, Lok A, Assies J, Ruhé HG, Koeter MW et al. DHEAS and cortisol/DHEAS-ratio in recurrent depression: state, or trait predicting 10-year recurrence? Psychoneuroendocrinology 2015; 59: 91-101.
38. Piccinelli M, Wilkinson G. Gender differences in depression. Critical review. Br J Psychiatry 2000; 177: 486-492.
39. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229-233.
40. Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry 2010; 44: 697-705.
41. Schaefer M, Schwaiger M, Pich M, Lieb K, Heinz A. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003; 36: S203-S206.
42. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2001; 7: 942-947.
43. Zahiu CD, Rimbas M. Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options. Maedica (Buchar) 2014; 9: 121-126.
44. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008; 103: 2766-2775.